KKR-owned Healthium Medtech and Temasek-backed Romsons Group have emerged as key bidders for a 70–80% stake in Delhi-based medical devices company BL Lifesciences, according to people familiar with the matter.
The transaction could value BL Lifesciences at around ₹1,800–2,000 crore. KPMG is advising the promoters on the proposed stake sale.
BL Lifesciences is a fourth-generation family-owned company with a portfolio spanning cardiac surgery, critical care, interventional cardiology, anaesthesia and surgical care. Its products include perfusion systems such as heart-lung packs, oxygenators and cardioplegia sets, along with cath-lab kits, central venous catheters, invasive pressure-monitoring systems, blood bags, surgical instruments and wound-care products.
The company has attracted interest from strategic and financial investors as India’s medical devices sector continues to see consolidation and expansion.
KKR and Temasek did not comment on the development, while BL Lifesciences Managing Director Sunil Aggarwal did not respond to an email seeking comments.
KKR acquired Healthium Medtech in 2024 for about ₹7,000 crore after outbidding a consortium comprising Mankind Pharma, ChrysCapital and Novo Holdings.